Drug intelligence / Profile preview

HPIV3-EbovZ GP vaccine

Development stage: Unknown
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

HPIV3-EbovZ GP vaccine is a recombinant vaccine candidate that uses human parainfluenza virus type 3 (HPIV3) as a vector to express the glycoprotein (GP) of Zaire ebolavirus (EBOV). It is designed to be administered intranasally, which induces immune responses both in the respiratory tract and systemically. The vaccine generates both humoral and cellular immune responses against Ebola virus and has shown protection in animal models including non-human primates, guinea pigs, and ferrets.

Other names: Human parainfluenza virus type 3-vectored Ebola virus glycoprotein vaccine

Targets

Zaire ebolavirus glycoprotein

Beyond the preview

Go deeper on HPIV3-EbovZ GP vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HPIV3-EbovZ GP vaccine.

Explore the full profile